{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-038258","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2026-08-14T19:20:31+00:00","discovered_at":"2026-08-14T19:22:52.442200+00:00","generated_at":"2026-08-14T19:23:04.894357+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"HCW Biologics Q2 net loss widens to $5.2M; raises going-concern doubt","bullets":["Q2 2026 net loss $5.2M vs $1.9M YoY; six-month loss $1.7M vs $4.1M; revenue $135.6K vs $6.6K.","HCW9302 Phase 1: all 3 patients in 3 µg/kg cohort showed ≥25% SALT score reduction; no dose-limiting toxicities; full readout Q4 2026.","Re-acquired ex vivo rights to HCW9206 from AlloTera; pursuing partner for CAR-T reagent market.","Raised $5.6M in May/July private placements; officers/directors participated.","Company expresses substantial doubt about going concern for next 12 months; Nasdaq compliance regained but monitor possible."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-038258","json":"https://secwatch.observer/filing/0001493152-26-038258.json","markdown":"https://secwatch.observer/filing/0001493152-26-038258.md","text":"https://secwatch.observer/filing/0001493152-26-038258.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226038258/0001493152-26-038258-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226038258/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T19:23:04.894357+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}